


## Iloperidone-d<sub>3</sub>

<b>Cat. No.:</b>	HY-17410S
<b>CAS No.:</b>	1071167-49-1
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>24</sub> D <sub>3</sub> FN <sub>2</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	429.5
<b>Target:</b>	Dopamine Receptor; 5-HT Receptor; Isotope-Labeled Compounds
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### SOLVENT & SOLUBILITY

<b>In Vivo</b>	<p>1. Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 1.14 mg/mL (2.65 mM); Clear solution</p> <p>2. Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: 1.14 mg/mL (2.65 mM); Suspended solution; Need ultrasonic</p>
----------------	---

### BIOLOGICAL ACTIVITY

<b>Description</b>	Iloperidone-d <sub>3</sub> is the deuterium labeled Iloperidone. Iloperidone (HP 873) is a D <sub>2</sub> /5-HT <sub>2</sub> receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms[1][2].
<b>IC<sub>50</sub> &amp; Target</b>	D <sub>3</sub> Receptor
<b>In Vitro</b>	<p>Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Kongsamut, S., et al., Iloperidone binding to human and rat dopamine and 5-HT receptors. *Eur J Pharmacol*, 1996. 317(2-3): p. 417-23.
- [3]. Sainati, S.M., et al., Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. *J Clin Pharmacol*, 1995. 35(7): p. 713-20.
- [4]. Albers, L.J., A. Musenga, and M.A. Raggi, Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? *Expert Opin Investig Drugs*, 2008. 17(1): p. 61-75.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA